Get the Daily Brief
Latest Biotech News
Precede raises $84M to scale liquid‑biopsy partnerships with pharma
Precede Biosciences closed an $83.5 million Series B and a $20 million credit facility to expand its liquid‑biopsy platform and capacity for pharma collaborations. Investors include Labcorp...
Soley nets $200M Series C — advancing stress‑modulation therapeutics toward INDs
Soley Therapeutics closed a $200 million Series C to advance its cell‑stress sensing platform and multiple clinical candidates, with a particular focus on oncology. The company plans IND filings...
Caldera launches with $112M: China‑origin bispecific enters clinic for IBD
Caldera Therapeutics launched with $112.5 million in combined Series A and A‑1 financing to advance CLD‑423, a dual‑target bispecific licensed from China’s Qyuns Therapeutics for inflammatory...
Verana buys COTA for $52M — real‑world data capabilities expand into oncology
Verana Health acquired oncology‑focused RWD provider COTA Healthcare for $52 million, merging complementary specialty datasets and analytics to serve more therapeutic areas. The combined company...
Illumina’s billion-cell atlas: AI drug discovery gets a data engine
Illumina announced the launch of its Billion Cell Atlas, a genome‑wide perturbation dataset that the company says will reach one billion single‑cell measurements and support AI‑driven drug...
AbbVie licenses PD‑1/VEGF bispecific from RemeGen: $650M upfront, $5B in milestones
AbbVie struck a global licensing agreement with China’s RemeGen for RC148, a PD‑1/VEGF bispecific, paying $650 million upfront and leaving up to $4.95 billion in development and commercial...
FDA clears Zycubo: first‑ever therapy for Menkes disease
The U.S. Food and Drug Administration approved Zycubo (copper histidinate, CUTX‑101) as the first treatment for Menkes disease, granting Sentynl Therapeutics the initial U.S. approval for a rare...
Proxima raises $80M seed: AI‑driven proximity medicines backed
Proxima (formerly VantAI) closed an $80 million oversubscribed seed round to develop AI‑designed proximity‑modulating drugs that rewire protein interactions. Led by DCVC with participation from...
Precede raises $84M — pairs liquid biopsy with next‑gen precision drugs
Precede Biosciences closed roughly $83.5–$84 million in financing (Series B plus a $20 million credit facility) to scale its liquid biopsy platform and expand partnerships with pharma. The Boston...
Caldera launches with $112.5M: China‑sourced IBD bispecific enters clinic
Caldera Therapeutics announced its launch with $112.5 million in combined Series A and Series A‑1 financing and began dosing healthy volunteers in a Phase I study of CLD‑423, a bispecific...
Natera leans on Signatera growth — phased‑variant MRD upgrade due mid‑2026
Natera reported accelerated Signatera minimal residual disease (MRD) growth and previewed product and regulatory milestones at JPM. The company said Q4 revenue was its fastest quarter for...
FDA asks Lilly, Novo to remove suicide warnings from GLP‑1 labels
The U.S. Food and Drug Administration told manufacturers of several GLP‑1 receptor agonists used for obesity that its post‑market review found no increased risk of suicidal ideation or behavior;...
Jazz sells priority review voucher for $200M — top price in a decade
Jazz Pharmaceuticals sold a priority review voucher to an undisclosed buyer for $200 million, the highest reported price for such a voucher since 2016. Jazz will receive half the proceeds and the...
Soley lands $200M Series C: pushes stress‑reduction drugs toward clinic
Soley Therapeutics closed a $200 million Series C to advance a portfolio of stress‑reducing drug candidates into the clinic, with a focus on oncology—including a lead AML program, SOL‑001—and...
Illumina launches billion‑cell atlas — AI drug discovery scale‑up
Illumina unveiled the Billion Cell Atlas, a genome‑wide genetic perturbation dataset designed to accelerate AI‑driven drug discovery. The company says the atlas will provide high‑resolution maps...
Nvidia inks multi‑partner AI pacts — pharma and lab giants join
Nvidia expanded its push into life sciences by announcing partnerships and co‑innovation investments with pharmaceutical and lab companies, including a five‑year, $1 billion collaboration with Eli...
AbbVie buys ex‑China rights to PD‑1/VEGF bispecific — $650m up front
AbbVie struck an exclusive, ex‑China licensing deal for RemeGen’s PD‑1/VEGF bispecific RC148, paying $650 million up front and creating the potential for multibillion‑dollar milestones. Under the...
Proxima (formerly VantAI) raises $80M — AI for proximity medicines
Proxima, the Roivant‑founded drug discovery firm formerly known as VantAI, closed an $80 million seed round to develop AI‑driven proximity‑modulating drugs that target protein‑protein...
Caldera launches with $112.5M — China‑sourced bispecific enters clinic
Caldera Therapeutics announced its launch with $112.5 million in combined Series A/A‑1 financing and dosed the first healthy volunteers in a Phase I study of CLD‑423, a dual‑target bispecific for...
Precede banks $83.5M — liquid biopsy platform scales for drug development
Precede Biosciences raised $83.5 million in Series B financing plus a $20 million credit facility to expand its liquid biopsy platform for pharma partnerships and clinical trials. The Boston...